scholarly journals Soluble Receptor for Advanced Glycation End Products and Its Correlation with Vascular Damage in Adolescents with Obesity

2019 ◽  
Vol 92 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Reyna Rodríguez-Mortera ◽  
Claudia Luevano-Contreras ◽  
Sergio Solorio-Meza ◽  
Armando Gómez-Ojeda ◽  
Russell Caccavello ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Vascular Damage ◽  
Atherogenic Index ◽  
Stiffness Index ◽  
Model Assessment ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Glycation End Products ◽  
End Products

Objective: The aim of this study was to evaluate soluble receptor for advanced glycation end products (sRAGE) and advanced glycation end products (AGEs) in adolescents with and without obesity (OB) and their correlation with vascular damage. Methods: This is a cross-sectional study with 15–19 years old adolescents: 33 with OB and 33 with normal weight (NW), each group included 17 male and 16 female. Lipid profile, insulin, carboxymethylysine (CML), sRAGE, total AGEs, and dietary AGEs intake (dAGEs) were evaluated. Vascular damage was measured by flow-mediated vasodilation (FMD) and arterial stiffness index (Iβ). Homeostatic model assessment-insulin (HOMA-IR) and atherogenic index (AI) were calculated. Results: The group with OB had higher triglycerides (TG; p < 0.0001), AI (p < 0.001), HOMA-IR (p < 0.0001), dAGEs intake (p < 0.0001), lower CML (p = 0.05), total AGEs (p < 0.01), sRAGE (p < 0.001), and FMD (p < 0.002). In the total group, sRAGE correlated with AI (r = –0.26 p = 0.037); in the NW group, CML correlated with Iβ (r = –0.36; p = 0.037); and in the group of adolescents with OB, sRAGE correlated with FMD (r = –0.37; p = 0.037) and Iβ (r = 0.47; p = 0.006), while CML and total AGEs correlated with AI, p = 0.007 and p < 0.01, respectively). Conclusions: The group of adolescents with OB showed higher cardiometabolic risk as shown by higher TG, AI, HOMA-IR, and lower sRAGE and FMD. sRAGE correlated negatively with FMD and positively with Iβ, so it could be suggested as a biochemical marker of impaired endothelial function.

Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria

2015 ◽  
Vol 13 (2) ◽  
pp. 259-264
Author(s):  
Huan Zheng ◽  
Lingyan Yuan ◽  
Nanzi Xie ◽  
Huifeng Xu ◽  
Xiaoyun Xie ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Advanced Glycation End Products Levels and Carotid Intima Media Thickness in Patients With Rheumatoid Arthritis

2019 ◽  
Vol 10 (2) ◽  
pp. 58
Author(s):  
Ines KNANI ◽  
Hassan BOUZIDI ◽  
Albert LECUBE ◽  
Jawhar GHARBI ◽  
Mohsen KERKENI
Keyword(s):  
Rheumatoid Arthritis ◽  
Advanced Glycation End Products ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Cross Sectional Study ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Media Thickness ◽  
Glycation End Products ◽  
End Products

Introduction: No data regarding the relationship of carotid intima media thickness (IMT) and serum advanced glycation end products (AGEs) levels in patients with rheumatoid arthritis (RA). The aim of this study is to evaluate the association between IMT and serum pentosidine, CML and MGO levels in patients with longstanding RA.Methods: In a cross-sectional study, 80 consecutive RA patients with longstanding disease were included and compared with 30 age and sex-matched healthy controls. IMT was measured using ultrasonography. AGEs such as pentosidine, Ne-carboxymethyllysine (CML) and methylglyoxal (MGO) as an intermediate of glycation, were determined by ELISA.Results: Serum pentosidine, CML and MGO levels were increased in RA patients vs control subjects (P = 0.001; P < 0.001; P < 0.001 respectively). IMT was increased with disease activity of RA (P = 0.004) and was associated with serum pentosidine (r = 0.460, P < 0.001), serum CML (r = 0.549, P < 0.001) and serum MGO (r = 0.658, P < 0.001). Furthermore, in a multiple stepwise regression analysis CML and MGO were independently associated with IMT (b= 0.333, P = 0.007; b = 0.690, P < 0.001, respectively).Conclusion: serum pentosidine, CML and MGO were increased in RA patients and were significantly related to IMT. Serum CML and MGO were independently associated with IMT.

scholarly journals Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Eva O. Melin ◽  
Jonatan Dereke ◽  
Magnus Hillman
Keyword(s):  
Type 1 Diabetes ◽  
Advanced Glycation End Products ◽  
Inflammatory Responses ◽  
Lipid Lowering ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Lipid Lowering Drugs ◽  
Glycation End Products ◽  
End Products

Abstract Background The receptors for advanced glycation end products (RAGE) are increased in atherosclerotic plaques. Soluble (s)RAGE decreases, whereas the extracellular newly identified receptor for advanced glycation end products (EN-RAGE) increases inflammatory responses mediated by RAGE. The aims were to explore whether sRAGE, EN-RAGE and the EN-RAGE/sRAGE ratio, were associated with the use of lipid-lowering drugs (LLD) and/or antihypertensive drugs (AHD) in patients with type 1 diabetes (T1D). Methods Cross-sectional design. T1D patients were consecutively recruited from one diabetes clinic. Blood samples were collected, supplemented with data from electronic health records. sRAGE and EN-RAGE were analysed by enzyme linked immunosorbent assays. An EN-RAGE/sRAGE ratio was calculated. Adjustments were performed with inflammatory and metabolic variables, s-creatinine, depression, smoking, physical inactivity, medication, and cardiovascular complications. Multiple regression analyses were performed. Results In this study 283 T1D patients (men 56%, 18–59 years) were included. One-hundred and thirty LLD users compared to 153 non-users had lower levels of the EN-RAGE/sRAGE ratio (P = 0.009), and 89 AHD users compared to 194 non-users had lower levels of sRAGE (P = 0.031). The use of LLD (inversely) (B coefficient − 0.158, P = 0.033) and the use of AHD (B coefficient 0.187, P = 0.023) were associated with the EN-RAGE/sRAGE ratio. sRAGE (Lg10) (per unit) (adjusted odds ratio (AOR) = 3.5, 95% CI = 1.4–9.1, P = 0.009), EN-RAGE (Lg10) (per unit) (inversely) (AOR 0.4, 95% CI = 0.2–1.0, P = 0.046), age (P <  0.001), and triglycerides (P <  0.029), were associated with LLD. sRAGE (Lg10) (per unit) (inversely) (AOR = 0.2, 95% CI = 0.1–0.5, P = 0.001), diabetes duration, triglycerides, s-creatinine, and systolic BP (all P values < 0.043), were associated with AHD. Conclusions Higher sRAGE levels and lower EN-RAGE levels were linked to the use of LLD, whereas lower sRAGE levels were linked to the use of AHD. No other variables but the use of LLD and the use of AHD were linked to the EN-RAGE/sRAGE ratio. This may be of major importance as sRAGE is an inhibitor and EN-RAGE is a stimulator of inflammatory processes mediated by RAGE.

Relation of Soluble Receptor for Advanced Glycation End Products to Predict Mortality in Patients With Chronic Heart Failure Independently of Seattle Heart Failure Score

2011 ◽  
Vol 107 (6) ◽  
pp. 938-944 ◽  
Author(s):  
Sergio Raposeiras-Roubín ◽  
Bruno K. Rodiño-Janeiro ◽  
Lilian Grigorian-Shamagian ◽  
María Moure-González ◽  
Ana Seoane-Blanco ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products
Sign in / Sign up

Export Citation Format

Share Document